{"schema_version":"secwatch.filing_event.v1","accession":"0002046386-26-000007","form_type":"8-K","ticker":"MDLN","cik":"0002046386","company_name":"Medline Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.112314+00:00","generated_at":"2026-05-16T00:30:46.293783+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medline Q4 net income down 37.7% to $180M; FY25 EBITDA up 3.2%; guides FY26 organic sales growth 8-9%","bullets":["Q4 net sales $7.8B (+14.8% YoY); net income $180M (-37.7%); Adj. EBITDA $805M (flat).","FY25 net sales $28.4B (+11.5%); net income $1.2B (-3.6%); Adj. EBITDA $3.5B (+3.2%).","FY25 organic sales growth 10.5%; net cash from ops $1.7B; Free Cash Flow $1.3B.","FY26 guidance: organic sales growth 8-9%; Adj. EBITDA $3.5-3.6B.","Margins pressured by tariffs and higher costs; $2.4B in new customer signings in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0002046386-26-000007","json":"https://secwatch.observer/filing/0002046386-26-000007.json","markdown":"https://secwatch.observer/filing/0002046386-26-000007.md","text":"https://secwatch.observer/filing/0002046386-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2046386/000204638626000007/0002046386-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2046386/000204638626000007/mdln-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:30:46.293783+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}